Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; the references it cites are not checked yet; 95 of the 162 sources its claims cite were checked for support.

Gastrointestinal Adverse Effects of Anti-Obesity Medications in Non-Diabetic Adults: A Systematic Review

Open access

Abstract

Background: With rising obesity rates, pharmacological interventions are increasingly used in non-diabetic adults. While being effective in managing weight, these agents frequently cause gastrointestinal (GI) side effects, affecting adherence and long-term outcomes. Objective: To systematically evaluate the frequency, severity, and types of GI adverse effects (AEs) associated with anti-obesity medications in obese adults without diabetes. Methods: Following PRISMA 2020 guidelines, PubMed, Google Scholar, BMJ, and Web of Science were searched (last search July 2025). Eligible studies included randomized controlled trials, non-randomized trials, cohort studies, cross-sectional, and case–control studies. Only reports of GI AEs in non-diabetic adults were included. Risk of bias was assessed using Cochrane RoB 2 and Newcastle–Ottawa scales. Results: Out of 733 articles screened, 12 studies met predefined inclusion criteria, including one large cohort of 18,386 participants, along with randomized and observational trials of smaller size. The most frequently reported GI symptoms were nausea, vomiting, diarrhea, and constipation, predominantly with GLP-1 receptor agonists such as semaglutide and tirzepatide, especially during dose escalation. Orlistat commonly linked to steatorrhea and flatulence, while phentermine was associated with reduced GI motility. Newer agents, including retatrutide and orforglipron, also demonstrated notable GI side effect profiles. Natural products and investigational agents reported fewer adverse events but lacked long-term data and standardized reporting. Limitations: Evidence was limited by heterogeneity in study design and inconsistent reporting of GI outcomes. Conclusion: GI side effects are common across anti-obesity medications, particularly GLP-1 receptor agonists. Although generally mild to moderate, these symptoms can impact adherence and lead to treatment discontinuation. Tailored titration schedules, proactive patient counseling, and standardized adverse event reporting may improve tolerability. Further research is warranted to evaluate long-term GI outcomes and compare safety across emerging pharmacologic agents.

Overview

CoChat Summary

TL;DR

This systematic review of 12 studies found gastrointestinal adverse effects are common with anti-obesity medications in non-diabetic adults, especially GLP-1 receptor agonists, and are generally mild to moderate and peak during dose escalation. Discontinuation due to GI events ranged roughly 1–17%, highest with high-dose incretin-based therapies.

Key findings

  • Across 12 included studies, GI AEs were the most frequent treatment-emergent events; nausea, vomiting, diarrhea, and constipation predominated, especially with GLP-1 receptor agonists such as semaglutide and tirzepatide during dose escalation. In STEP 1, GI disorders occurred in 74.2% with semaglutide vs. 47.9% with placebo; nausea 44.2% vs. 17.4%, diarrhea 31.5% vs. 15.9%, vomiting 24.8% vs. 6.6%, constipation 23.4% vs. 9.5%, and discontinuation due to GI events 4.5% vs. 0.8%.
  • Orlistat was consistently associated with oily stools, fecal urgency, and flatulence with discharge in 15–30% of users. Phentermine 15 mg produced abdominal pain 0.5%, constipation 3.5%, dry mouth 6.3%, nausea 0.5%, and vomiting 0.3%; at 30 mg, rates were 2.4%, 4.1%, 13.9%, 1.1%, and 0.8%, respectively.
  • In a comparative cohort of 18,386 participants, semaglutide vs. tirzepatide showed similar event rates per 1000 person-years: bowel obstruction 6.26 vs. 5.54 (HR 1.12; 95% CI 0.63–1.97), cholecystitis 6.5 vs. 5.06 (HR 1.25; 95% CI 0.70–2.21), cholelithiasis 11.89 vs. 12.66 (HR 0.94; 95% CI 0.63–1.39), and gastroenteritis 19.75 vs. 20.07 (HR 1.00; 95% CI 0.73–1.37).
  • Discontinuation due to GI events ranged roughly 1–17%, highest with high-dose incretin-based therapies; gallbladder-related events were uncommon (<2%) but slightly more prevalent with incretin drugs. Natural and investigational agents produced the fewest reported GI events but were supported by small, short-term studies.

Methods

  • PRISMA 2020 systematic review prospectively registered in PROSPERO (CRD420251113277); searched PubMed, Google Scholar, BMJ archive, and Web of Science, with last search July 2025. Eligible studies included randomized controlled trials, non-randomized trials, cohort studies, cross-sectional studies, case–control studies, and interventional clinical trials in English, published 2020–2025, in non-diabetic adults ≥18 years.
  • From 733 records identified, 12 studies met all inclusion criteria and were included; one large cohort had 18,386 participants. Risk of bias was assessed with Cochrane RoB 2 and Newcastle–Ottawa scales, with articles scoring above 70% considered eligible.
  • A quantitative meta-analysis was not feasible due to heterogeneity in study design, outcome definitions, and reporting methods; findings were synthesized narratively. No formal GRADE scoring, publication bias testing, subgroup analysis, or sensitivity analysis was conducted.

Limitations

  • The paper states that evidence was limited by heterogeneity in study design and inconsistent reporting of GI outcomes; meta-analysis was not feasible, formal GRADE and publication bias testing were not performed, and few studies addressed potential confounders such as preexisting GI conditions, dietary patterns, or concomitant medication use.
  • The paper states that symptom grading was inconsistent, no study used GI-specific severity frameworks such as CTCAE, and none assessed patient satisfaction or GI symptom-specific quality-of-life instruments; natural and investigational products relied on limited short-term data.
  • Evident from the text: only English-language articles from 2020–2025 were included, no separate detailed protocol was prepared, no amendments were made to the registration, and reporting bias was not formally assessed because unpublished data and trial registries were outside the review’s scope.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/medicina61111987

Cites

Statistics

Nothing to recompute.

Figures

Figure 1 PRISMA Flow Diagram. BMJ: British Medical Journal; n: Number; PCOS: Polycystic Ovarian Syndrome; PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analysis.
Figure 1 PRISMA Flow Diagram. BMJ: British Medical Journal; n: Number; PCOS: Polycystic Ovarian Syndrome; PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analysis.CC BY · PubMed Central

Verification

Claims the paper makes

42 Valid · 4 Not valid · 29 Not checked · 54 Own results and interpretations

67 more claims · 34 with their cited sources checked

Create a free account to see all 129 claims and to verify the 67 references still open.

See all claims — free account
  • Probably not a substantial claim. 20
  • It may state two separate claims as one. 49

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

The citation lists are queued

They are fetched later and appear here then.

References 24 · Cited by 13

Metadata

Authors
Takrori, E., Peshin, S., & Singal, S.
Affiliations
  • Alfaisal University (SA)
  • Norton Community Hospital (US)
  • East Tennessee State University (US)
Corresponding author
Peshin, Supriya
Venue
Medicina
Publisher
MDPI AG
Published
2025-11-05
Volume
61
Issue
11
Pages
1987
ISSN
  • 1010-660X (ISSN-L)
  • 1648-9144
OpenAlex
W4415929925
Cited by
13
References
24
Citations by year
2026: 12 · 2025: 1
FWCI
1.75
Type
journal article
Language
en
Open access
Locations
  • Medicina (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
anti-obesity drugs, gastrointestinal adverse effects, non-diabetic adults, obesity, GLP-1 receptor agonists, semaglutide, tirzepatide, orlistat, phentermine, retatrutide, orforglipron, nausea, vomiting, diarrhea, constipation, steatorrhea, medication adherence, dose escalation
MeSH terms
Adult, Gastrointestinal Diseases, Humans, Obesity, Anti-Obesity Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Gastrointestinal Adverse Effects of Anti-Obesity Medications in Non-Diabetic Adults: A Systematic Review. https://app.cochat.ai/papers/10.3390/medicina61111987
The paper
Takrori, E., Peshin, S., & Singal, S. (2025). Gastrointestinal Adverse Effects of Anti-Obesity Medications in Non-Diabetic Adults: A Systematic Review. Medicina. https://doi.org/10.3390/medicina61111987

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.